PROMPERÚ
From April 5 to 7, Peru was represented in Berlin at the latest edition of Fruit Logistica 2022, the world's leading fresh fruit and vegetable fair, reports the Commission for the Promotion of Peru for Exports and Tourism (PROMPERÚ).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220416005003/en/
“This time around, Peru's business objective at Fruit Logistica will be to achieve 200 million USD in prospective business for the next 12 months and to generate 6,000 business contacts with the Peruvian delegation, in addition to consolidating a diversified and quality exportable supply,” stated the executive president of PROMPERÚ, Amora Carbajal.
“The sustainability of the Peruvian exportable supply will be a differentiating element at the fair. This is a focus that has been developing within our society and within the business models of Peruvian agro-export companies, improving their competitiveness and reducing environmental impacts through responsible water management, efficient carbon footprint management and fair trade strategies,” said the head of PROMPERÚ.
Fruit Logistica 2022 made it possible to consolidate the position of the Super Food Peru, Pisco, Spirit of Peru and Cafés del Perú brands. The commercial promotion campaign included activations and sampling of exotic fruits and specialty coffees in the national pavilion, in addition to pisco tastings, and typical regional dances.
The delegation led by PROMPERÚ was made up of the Ministry of Agriculture and Irrigation (MIDAGRI), Sierra and Selva Exportadora, Agro Ideas, the Embassy of Peru in Germany, directors of unions and the Association of Agricultural Producer Unions of Peru (AGAP).
Exports
Peruvian food sector exports to the European Union in 2021 reached 3,432 billion USD, growing by more than 13%. The main exports include fresh and dried avocados (604 million USD / +32.3%), unroasted coffee (422 million USD / +23.9%), fresh blueberries (360 million USD / +7.0%), fresh grapes (306 million USD / +28.3%), fresh mangoes (175 million USD / +0.7%), among other products.
In addition, foreign sales of fruit and vegetables amounted to 2,103 billion USD in this same period, with a growth of more than 17%, due to the notable performance of the Netherlands (1,132 billion USD / +19.6%), the United Kingdom (346 million USD / +9.4%), Spain (324 million USD / +22.5%) and Germany (56 million USD / +24.5%). These markets make up 95% of the value exported to the European Union.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220416005003/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altris and Draslovka Partner to Scale Europe’s First Sodium-Ion Battery Technology Supply Chain15.1.2026 14:00:00 CET | Press release
Altris, a Swedish sodium-ion battery developer, and Draslovka, a global leader in specialty chemicals, have entered a strategic partnership to build Europe’s first industrial-scale sodium-ion cathode value chain. Under the comprehensive agreement that includes a total 19.3 MEUR in-kind investment by Draslovka in Altris, the two companies will scale fully connected production of Altris’ patented sodium-ion cathode active material (CAM) at Draslovka’s facility in Kolín, Czech Republic, supplying up to 350 tonnes of CAM annually. Draslovka and Altris are partnering to convert an existing line at Draslovka’s Kolín facility for production of Altris’ sodium-ion CAM, enabling rapid time-to-market and capital-efficient scale-up. Once ramped, the line will support production of up to 350 tonnes annually – a European-controlled supply equivalent to around 175 MWh of sodium-ion cell capacity. As part of the agreement, Draslovka is making a new in‑kind 19.3 MEUR strategic investment in Altris to c
CPP Investments Increases Commitment to Canadian Market through Northleaf Capital Partners15.1.2026 14:00:00 CET | Press release
Canada Pension Plan Investment Board (CPP Investments) and Northleaf Capital Partners (Northleaf) today announced a significant expansion of their longstanding Canadian investment partnership, supporting the growth and scaling of domestic private companies. CPP Investments has committed to invest an additional C$750 million through its established Canadian mid-market program managed by Northleaf, bringing CPP Investments’ cumulative commitments to the manager to more than C$3 billion since inception. The customized mandate focuses on maximizing net returns through a diversified strategy that includes primary fund commitments to small and mid-market Canadian buyout funds, secondary investments, and direct co-investments focused on the domestic market. “There are compelling investment opportunities in the Canadian market, and our two-decade long partnership with Northleaf has proven to be an effective and scalable way to invest in homegrown businesses with patient, long-term capital,” sa
Vantage Data Centers Completes £200M Tap of Existing £600M Industry-First EMEA Data Center Asset-Backed Securitization (ABS) and Adds New £54M Class B Tranche15.1.2026 14:00:00 CET | Press release
Financing will support the company’s expansion across EMEA to keep pace with AI and cloud demand Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced it has raised an additional £254 million in securitized term notes. £200 million was raised through a tap of the existing Class A-2 Notes while £54 million was raised from the new Class B Tranche. This builds on Vantage’s debut public issuance in 2024 raising £600 million, which was the first-ever EMEA data center ABS completed in sterling. The Class A-2 Notes are rated A-, A (low) and A by Standard & Poor’s, Morningstar DBRS and Scope Ratings, respectively. The Class B Notes are rated BBB- by Standard & Poor’s and BBB by Morningstar DBRS and Scope Ratings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115777091/en/ Vantage’s 148MW Cardiff, Wales, campus is one of Europe’s largest hyperscale data center campuses. The new notes
QPS Selects Oracle Argus Safety Database to Enhance Pharmacovigilance in Clinical Trials15.1.2026 13:57:00 CET | Press release
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/ Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC. The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements. “Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Dere
InterAx and Alveus Announce Strategic Research and Licensing Agreement to Develop Differentiated Therapeutic Candidate for Metabolic Disease15.1.2026 13:30:00 CET | Press release
InterAx Biotech Ltd (“InterAx”) and Alveus Therapeutics Inc. (“Alveus”) today announced a strategic research collaboration and licensing agreement to develop a differentiated small molecule candidate for metabolic disease to deliver durable weight loss with superior tolerability. This partnership forms a joint research effort on a target and modality of established but untapped therapeutic interest by combining InterAx’s Deep Signal™ discovery platform – designed to optimize candidates toward superior signaling profiles – with Alveus’s deep R&D expertise and leadership in obesity, diabetes, and cardiometabolic disease. While financial terms remain undisclosed, the agreement includes an upfront payment and eligibility for future development, regulatory, and commercial milestones. “We are thrilled to join forces with Alveus to advance a highly differentiated therapeutic candidate designed to overcome the limitations of today’s obesity medications,” said Andrew Roberts, CEO of InterAx. “O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom